The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer’s disease - 03/02/23
, Alzbeta Dlabkova b , Jakub Hort c, d , Francesco Angelucci c, d, Jaroslav Pejchal b, Kamil Kuca a, e , Zbysek Pavelek a, Jana Zdarova Karasova b, c, Michal Novotny a, ⁎ Abstract |
Background |
The acetylcholinesterase inhibitor donepezil is administered as a treatment for Alzheimer's disease (AD). However, the appropriate donepezil dosage is still a matter of debate. Methods: Forty AD patients receiving 10 mg/day of donepezil were randomly divided into four groups based on the time of plasma and cerebrospinal fluid (CSF) sampling: 6 h (n = 5), 12 h (n = 12), 18 h (n = 6) and 24 h (n = 17) after donepezil administration. High-performance liquid chromatography measured the donepezil concentration in plasma samples and CSF samples collected at 4-time points. Results: Plasma and CSF levels among the groups were not significantly different. Conversely, the CSF/plasma donepezil concentration ratio considerably increased in the 24 h group compared to the 6 h (p < 0.005) and 12 h (p < 0.05) groups. Conclusion: The measurement of the CSF/plasma donepezil concentration ratio could be used to better evaluate the optimal dose of donepezil.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Donepezil is currently considered one of the most promising pharmacological tools. |
• | CSF/plasma donepezil concentration ratio was significantly increased in the 24 h group. |
• | CSF/plasma donepezil concentration ratio could be used for the evaluation of the optimal dose. |
Keywords : Alzheimer’s disease, Donepezil, AChE-Is, Plasma, CSF, Ratio
Plan
Vol 159
Article 114223- mars 2023 Retour au numéro
Article précédent
- PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study
- Sergio Salgüero, Óscar Brochado-Kith, Ana Virseda Verdices, Juan Berenguer, Juan González-García, Isidoro Martínez, Cristina Díez, Víctor Hontañón, Leire Pérez-Latorre, Amanda Fernández-Rodríguez, María Ángeles Jiménez-Sousa, Salvador Resino
- Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
- Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A.M. Mulder, Esther Oomen-de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H.N. van Schaik, Sander Bins
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?